Background
==========

Each year, more than 1 million people are diagnosed with colorectal cancer. As a result, 715 000 deaths were reported in 2010 around the world. In 1990, only 490 000 deaths were reported. Colorectal cancer is the second most common cancer in females and the third most common cancer in males \[[@b1-medscimonit-20-1369],[@b2-medscimonit-20-1369]\]. Due to the epidemiologic effects of colorectal cancer, many observers attempt to study prognostic factors for cancer-related mortality and survival.

According to the American Joint Committee on Cancer, tumor-node metastasis (TNM) systems and non-metastatic, lymph node-invaded colon cancers are at the 3^rd^ stage. As a result, lymph node invasion is the dominant prognostic factor for non-metastatic colon cancer and is the basic indicator for adjuvant treatment after curative resection. Some patients will have recurrence after curative resection, which may be due to residual nodal disease after insufficient lympadenectomy. According to quality standards of the National Comprehensive Cancer Network (NCCN) and the American College of Physicians, a minimum number of 12 lymph nodes are advised for resection and pathological examination. Pathological examination of a minimum of 12 lymph nodes may help to correctly differentiate stage 3 patients from stage 1--2 patients. The metastatic lymph node ratio (MLNR) is the number of metastatic lymph nodes divided by the number of totally resected lymph nodes. The MLNR ranges between 0 and 1. Recent studies have shown the importance of the MLNR in estimating prognosis of colon cancer, showing that the MLNR is more valuable than the N value of the TNM stage \[[@b3-medscimonit-20-1369]\].

The purpose of this study was to evaluate the prognostic importance of the MLNR in stage 3 colon cancer patients and to determine the cut-off value at which overall survival (OS) and disease-free survival (DFS) change.

Material and Methods
====================

Fifty-eight third-stage colon cancer patients were included in this retrospective study. These patients were diagnosed and operated on at Vakif Gureba Training and Research Hospital (Istanbul, Turkey) between 2006 and 2011 and at Erzincan University Hospital (Erzincan, Turkey) between 2009 and 2014. A 4-year follow-up was included in the study. Follow-up protocols adhered to NCCN guidelines \[[@b4-medscimonit-20-1369]\]. The files of the patients were scanned and age, pre-operative values of Crp, Cea, Ca19-9, Afp, pathologic vascular, perineural, lymphatic, serosal involvement, and MLNR values were imported into Microsoft Excel (2007). The correlation among these values and the effectiveness of these parameters with regards to OS and DFS were studied. A cutoff value of 0.25 was determined for the MLNR and the effect of the MLNR on OS and DFS was studied. R0 resections were done on all patients. Exclusion criteria included patients who had to be operated on only urgently and patients with fewer than 12 resected lymph nodes. The power analysis of the study is 0.82 for MNLR value. This study was conducted according to the Declaration of Helsinki. Local ethics committee approval was obtained. Informed consent was obtained from all patients.

Statistical analysis
--------------------

Descriptive statistics such as frequency, arithmetic mean, standard deviation, and percentage were used to analyze the data. Non-parametric Mann-Whitney U and chi-squared tests were used for comparison. Spearman's rho correlation coefficient was used for correlation analysis. The Kaplan-Meier method was used for survival analysis. Multivariate analysis according to Cox regression was conducted for the parameters that were meaningful for univariate analysis. A 95% confidence interval, combined with a p-value less than 0.05, was considered statistically significant. We used SPSS v 17.0 (IBM Corporation, Armonk, NY, USA) for statistical analysis.

Results
=======

Fifty-eight patients were involved in this study: 20 females (34.5%) and 38 males (65.5%). The mean age was 59.2±13.8 years and the median of age value was 60. By the end of 4-year follow-up, 5 patients had died. All of the deceased patients had MLNRs ≥0.25. The 3-year survival rate for all patients was 74.3% and the DFS rate for all patients was 72.0%. The survival rates of each group are listed in [Table 1](#t1-medscimonit-20-1369){ref-type="table"}.

Descriptive values for age, Crp, Ca19-9, Cea, Afp, MLNR, overall follow-up time, and disease-free follow-up time are listed in [Table 2](#t2-medscimonit-20-1369){ref-type="table"} and the pathologic involvement of vascular, perineural, lymphatic, and serosal invasions are listed in [Table 3](#t3-medscimonit-20-1369){ref-type="table"}.

We list the correlations between age, Crp, Ca19-9, Cea, Afp, and MLNR in [Table 4](#t4-medscimonit-20-1369){ref-type="table"}. As age increases, Cea, Afp, and MLNR values decrease. As the MLNR increases, Crp, Ca19-9, Cea, and Afp values increase.

As shown in [Table 5](#t5-medscimonit-20-1369){ref-type="table"}, all variables except Afp were significant when compared with the MLNR groups.

As shown in [Table 6](#t6-medscimonit-20-1369){ref-type="table"}, all pathological involvements were statistically significant compared with the MLNR groups.

The mean OS time of each MLNR groups for the 4-year follow-up is listed in [Table 7](#t7-medscimonit-20-1369){ref-type="table"}. The log rank test yielded p=0.011 (p\<0.05). The mean OS time of the group with MNLR \<0.25 group was longer than the mean OS time of the group with MLNR ≥0.25. The mean DFS times of each of the MLNR groups for the 4-year follow-up are listed in [Table 7](#t7-medscimonit-20-1369){ref-type="table"}. The log rank test result was p=0.008 (p\<0.05). The mean DFS time of the group with MNLR \<0.25 group was longer than the mean DFS time of the group with MLNR ≥0.25.

The OS curves of the MLNR groups for the 3-year follow-up are shown in [Figure 1](#f1-medscimonit-20-1369){ref-type="fig"} and the DFS curves of the MLNR groups for the 3-year follow-up are shown in [Figure 2](#f2-medscimonit-20-1369){ref-type="fig"}.

The variables that were statistically significant for OS and DFS in the univariate analysis, including age (\< or ≥60 years) (p=0.003--0.043), Crp (\< or ≥0.9mg/dl) (p=0.035--0.04), Cea (\< or ≥5 ng/ml) (p=0.032--0.048), perineural invasion (negative or positive) (p=0.042--0.04), and the MLNR (\< or ≥0.25) (p=0.001--0.002); these parameters were used for multivariate analysis. Cox regression was also applied. As a result, only the MLNR (\< or ≥0.25) was statistically significant for OS and DFS ([Table 8](#t8-medscimonit-20-1369){ref-type="table"}).

Discussion
==========

For non-metastatic colon cancers, lymph node invasion is the most important prognostic factor. A correct evaluation is important for adjuvant treatment. To state that a patient is node negative, a large enough number of lymph nodes must be resected. Consensus guidelines set this threshold at 12 or above \[[@b4-medscimonit-20-1369]--[@b7-medscimonit-20-1369]\]. If enough lymph nodes cannot be resected, stage migration (the Will Rogers phenomenon) may be observed. Will Rogers stage migration states that for an increasing number of diagnoses, more disease-free people will be re-evaluated as patients. When these disease-free people (real patients) move from the disease-free people group to the patient group, the mean survival rates of people in the true disease-free group change. Similarly, the people who move will be healthier than patients in the previously-ill group. Therefore, the survival rates of patients in the group increase. In each group, there is a statistically significant increase in survival rate. Regardless of treatment changes, the early detection of cancer causes more time to pass in the patient group \[[@b8-medscimonit-20-1369],[@b9-medscimonit-20-1369]\]. Because the MLNR does not cause Will Rogers phenomenon as N value of the TNM stage, it is a better prognostic marker for gastric cancers \[[@b10-medscimonit-20-1369],[@b11-medscimonit-20-1369]\] and solid tumors \[[@b12-medscimonit-20-1369],[@b13-medscimonit-20-1369]\].

In the present study, as age decreases, Crp, Ca19-9, Cea, Afp, and MLNR values increase. These findings show the strength of the MLNR in the present study. Similar results (except Afp) were found when the MLNR was divided into 2 groups. The involvement status between the 2 groups (MLNR \<0.25 and MLNR ≥0.25) was statistically significant in the present study. Since vascular, perineural, lymphatic, and serosal invasions reveal tumor aggressiveness and these properties are correlated with the MLNR ≥0.25 group in the present study, a poor prognosis for the MLNR ≥0.25 group is expected. Park et al. \[[@b14-medscimonit-20-1369]\] constructed 3 groups based on the MLNR for individuals with stage 3 colon cancers who had 12 or more resected lymph nodes ([Table 9](#t9-medscimonit-20-1369){ref-type="table"}). These authors found that the DFSs of patients between the 3 groups were statistically significant. The DFS of the MLNR \>0.23 group was 55%, comparable to the results of DFS for our MLNR ≥0.25 group (54%). The OS and DFS of our results were similar, which may be due to the delayed diagnosis of recurrent tumors and the aggressiveness of recurrent tumors.

Ramos-Esquival et al. studied 3-year OSs and DFSs of 29 stage 3 colon cancer patients and determined a cut-off value of the MLNR of 0.25. In their retrospective study, the MLNR was the independent variable \[[@b15-medscimonit-20-1369]\]. Schumacher et al. determined a cut-off value of the MLNR of 0.18 for the DFS of 57 stage 3 colon cancer patients who had more than 12 lymph nodes resected \[[@b16-medscimonit-20-1369]\]. Chin et al. found that the MLNR was the only independent variable for the 5-year DFS of 490 patients with stage 3 colon cancers. These authors also found that the N value of the TNM was a dependent variable \[[@b17-medscimonit-20-1369]\]. Similar to the present study, Vaccaro et al. showed that the MLNR was an independent survey parameter and determined a cut-off value for the MLNR of 0.25 \[[@b18-medscimonit-20-1369]\] ([Table 9](#t9-medscimonit-20-1369){ref-type="table"}).

The certainty regarding metastatic lymph nodes increases as the number of resected lymph nodes increases. At the same time, prognoses can be improved by increasing the number of totally resected lymph nodes (i.e., achieving MLNR \<0.25). In the TNM classification, stage 3 colon cancers are broken into 3 substages: 3a, 3b, and 3c. This convention combines the T and N stages of the tumor. This decreases the prognostic importance of lymph node involvement. Furthermore, 1 metastatic lymph node may cause a change in stage or stage migration if an insufficient lymph node resection is performed. However, this effect will not be so pronounced in the case of the MLNR. The number of metastatic lymph nodes remains constant in the case of sufficient lymph node resection. However, the MLNR may change according to the operation and is dependent on the surgeon. Therefore, the prognosis of the patient may be improved in higher-quality surgeries.

It is likely that the exact number of metastatic lymph nodes is affected by the pathological evaluation (micrometastasis or metastatic cells cannot be evaluated as metastasis by pathology). Therefore, increasing the number of resected lymph nodes will increase patient safety. In this case, the MLNR will be above 0.25 if the lymph node resection was insufficient. On the other hand, the MLNR will be under 0.25 if a sufficient resection was done. The 0.25 threshold may have only mathematical importance, because the number of metastatic lymph nodes that are not evaluated as being metastatic by pathology will be reduced by increasing the number of resected lymph nodes. Therefore, the survival rate will increase because the patient will no longer have metastatic lymph nodes. In this viewpoint, the number of totally resected lymph nodes will be more important than the MLNR. An increased number of immune cells in colon cancer patients decreases lymph node metastasis and causes the MLNR to decrease. Furthermore, an increased number of immune cells reveals a strong host immunity or a less aggressive tumor biology, both of which lead to better survival. MLNR ≥0.25 stage 3 colon cancer patients may be evaluated as stage 4 and aggressive adjuvant treatment such as oxaliplatin may be added to fluorouracil-based chemotherapies, which are used worldwide for the treatment for stage 3 colon cancers.

Conclusions
===========

The disadvantage of the present study is the shortness of the follow-up time; however, recurrences were observed mostly within the first 2 years. There were fewer patients in the present study than in some other relevant studies, but patients who had fewer than 12 lymph nodes resected were excluded from the present study. This criterion increased the power of the study but decreased the total number of patients. Epidemiologic and experimental prospective studies are needed \[[@b19-medscimonit-20-1369],[@b20-medscimonit-20-1369]\].

As a result, the MLNR is an ideal prognostic marker for stage 3 colon cancer patients. A cut-off value of 0.25 for the MLNR represents the point at which the prognosis deteriorates.
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###### 

Survivals of each group.

  Three-year survivals   Overall survival rate   Disease-free survival rate
  ---------------------- ----------------------- ----------------------------
  MLNR \<0.25 group      .883                    .880
  MLNR ≥0.25 group       .563                    .540

###### 

Descriptive values for age, Crp, Ca19-9, Cea, Afp, MLNR, overall follow-up time, and disease-free follow-up time.

                                         Min.   Max.      Mean     Std. Dev.
  -------------------------------------- ------ --------- -------- -----------
  Age (years)                            29     84        59.2     13.83
  Crp (mg/dl)                            .201   20.000    4.533    5.844
  Ca19-9 (U/ml)                          .600   695.000   33.449   93.268
  Cea (ng/ml)                            .605   244.000   15.956   44.867
  Afp (ng/ml)                            .610   4.210     1.762    0.957
  MLNR                                   .034   0.929     0.286    0.247
  Overall follow-up time (months)        8      48        35.69    12.735
  Disease-free follow-up time (months)   6      48        35.29    13.456

###### 

Descriptive values for pathologic involvement of vascular, perineural, lymphatic, and serosal invasion.

  Invasion status   Frequency (n)   Percent (%)   
  ----------------- --------------- ------------- ------
  Vascular          −               39            67.2
  \+                19              32.8          
  Perineural        −               40            68.9
  \+                18              31.1          
  Lymphatic         −               35            60.3
  \+                23              39.7          
  Serosal           −               33            56.8
  \+                25              43.2          

###### 

Correlation analysis of age, Crp, Ca 19-9, Cea, Afp, and MLNR.

  Spearman's Rho   Age                                                         Crp                                                          Ca19-9                                                       Cea                                                          Afp                                                        MLNR
  ---------------- ----------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------ ---------------------------------------------------------- -------
  Age              1.000                                                                                                                                                                                                                                                                                                         
  Crp              −.206                                                       1.000                                                                                                                                                                                                                                             
  Ca19-9           .061                                                        .459[\*\*](#tfn2-medscimonit-20-1369){ref-type="table-fn"}   1.000                                                                                                                                                                                
  Cea              −.387[\*](#tfn1-medscimonit-20-1369){ref-type="table-fn"}   .124                                                         .375[\*\*](#tfn2-medscimonit-20-1369){ref-type="table-fn"}   1.000                                                                                                                   
  Afp              −.317[\*](#tfn1-medscimonit-20-1369){ref-type="table-fn"}   .513[\*\*](#tfn2-medscimonit-20-1369){ref-type="table-fn"}   .296[\*](#tfn1-medscimonit-20-1369){ref-type="table-fn"}     .043                                                         1.000                                                      
  MLNR             −.293[\*](#tfn1-medscimonit-20-1369){ref-type="table-fn"}   .642[\*\*](#tfn2-medscimonit-20-1369){ref-type="table-fn"}   .264[\*](#tfn1-medscimonit-20-1369){ref-type="table-fn"}     .496[\*\*](#tfn2-medscimonit-20-1369){ref-type="table-fn"}   .330[\*](#tfn1-medscimonit-20-1369){ref-type="table-fn"}   1.000

Correlation is significant at the 0.05 level (2-tailed);

Correlation is significant at the 0.01 level (2-tailed).

###### 

Comparison of MLNR groups with age, Crp, Ca 19-9, Cea, and Afp.

                  MLNR groups   Frequency (n)   Mean      Std. dev.   U       p
  --------------- ------------- --------------- --------- ----------- ------- -------------
  Age (year)      \<0.25        32              61.219    12.707      352.5   0.019\*
  ≥0.25           26            56.846          15.017                        
  Crp (mg/dl)     \<0.25        32              3.143     3.472       369.0   0.032\*
  ≥0.25           26            5.662           7.081                         
  Ca19-9 (U/ml)   \<0.25        32              28.980    33.055      264.5   0.018\*
  ≥0.25           26            38.950          135.725                       
  Cea (ng/ml)     \<0.25        32              5.100     13.137      115.0   0.000\*\*\*
  ≥0.25           26            24.777          58.163                        
  Afp (ng/ml)     \<0.25        32              1.667     1.138       414.0   0.975
  ≥0.25           26            1.839           0.683                         

###### 

Pathological involvement status compared with MLNR groups.

  Invasion status   \<0.25   ≥0.25   p    
  ----------------- -------- ------- ---- -------
  Vascular          −        30      9    0.04
  \+                2        17           
  Total             32       26           
  Perineural        −        28      12   0.03
  \+                4        14           
  Total             32       26           
  Lymphatic         −        32      3    0.000
  \+                0        23           
  Total             32       26           
  Serosal           −        29      4    0.009
  \+                3        22           
  Total             32       26           

###### 

Mean overall survival time of each MLNR groups for four-year follow-up time.

  Survivals                    MLNR     Mean (months)                     
  ---------------------------- -------- --------------- -------- -------- --------
  Overall survival time        \<0.25   42.313          1.208    39.945   44.680
  ≥0.25                        31.367   2.802           25.874   36.859   
  Overall                      37.727   1.549           34.691   40.763   
  Disease-free survival time   \<0.25   42.344          1.210    39.971   44.716
  ≥0.25                        30.838   2.883           25.187   36.488   
  Overall                      37.636   1.575           34.549   40.723   

###### 

Multivariate analysis of MLNR for survivals.

  Survivals               p      Exp (B)   95.0% CI for Exp (B)   
  ----------------------- ------ --------- ---------------------- -------
  Overall survival        .042   1.712     .982                   2.984
  Disease-free survival   .039   1.736     .997                   3.024

###### 

Miscellaneous studies about MLNR at stage 3 colon cancer.

  Author       Year                    Nature          Number of patients   Cutoff value
  ------------ ----------------------- --------------- -------------------- --------------
  Ramos        2010                    Retrospective   29                   0.25
  Schumacher   1998--2004              Retrospective   57                   0.18
  Chin         1995--2003              Retrospective   490                  0.4--0.7
  Vaccaro      1980--2005              Retrospective   362                  0.25
  Park         1996--2006              Retrospective   318                  0.059--0.23
  Present      2006--2011/2009--2014   Retrospective   58                   0.25
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